New mutations in TP53 gene drive resistance to p53-targeted cancer therapy

Mutations in the tumor suppressor TP53 are a common cause of cancer, making the altered protein an attractive target for therapeutics. Among them, the Y220C mutation is the ninth most frequent and it creates a small crevice in the mutant protein…

Continue Reading

News Source: medicalxpress.com